These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 6420643)

  • 1. [Cytotoxic activity of the leukocytes of chronic Chagas' disease patients against Trypanosoma cruzi].
    Olabuenaga SE; Rimoldi MT; Cardoni RL; Riera NE; Sánchez RA; Chiale P; de Bracco MM
    Medicina (B Aires); 1983; 43(2):168-74. PubMed ID: 6420643
    [No Abstract]   [Full Text] [Related]  

  • 2. Acquired cell-mediated immunodepression in acute Chagas' disease.
    Teixeira AR; Teixeira G; Macêdo V; Prata A
    J Clin Invest; 1978 Dec; 62(6):1132-41. PubMed ID: 107195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trypanosoma cruzi: infectivity and virulence of trypomastigotes incubated with leukocytes and serum from patients with Chagas' disease.
    Mosca W; Briceño L; Velasco J
    Acta Cient Venez; 1992; 43(5):290-4. PubMed ID: 1343741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Exoantigens of Trypanosoma cruzi. Epitopes reactive against immunoglobulins of patients with Chagas' disease].
    Gruppi A; Moretti ER; Basso B; Vottero-Cima E
    Medicina (B Aires); 1988; 48(2):161-6. PubMed ID: 3148093
    [No Abstract]   [Full Text] [Related]  

  • 5. Isotype of lytic antibodies in serum of Chagas' disease patients.
    Romeiro SA; Takehara HA; Mota I
    Clin Exp Immunol; 1984 Feb; 55(2):413-8. PubMed ID: 6421519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trypanosoma cruzi-sensitized T-lymphocyte mediated 51CR release from human heart cells in Chagas' disease.
    Teixeira AR; Teixeira G; Macêdo V; Prata A
    Am J Trop Med Hyg; 1978 Nov; 27(6):1097-1107. PubMed ID: 83110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro cellular immunity in Chagas' disease.
    Toledo Barros MA; Amato Neto V; Mendes E; Mota I
    Clin Exp Immunol; 1979 Nov; 38(2):376-80. PubMed ID: 118840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of antigens of culture forms of Trypanosoma cruzi and Trypanosoma rangeli recognized by sera from patients with chronic Chagas' disease.
    Grögl M; Kuhn RE
    J Parasitol; 1984 Oct; 70(5):822-4. PubMed ID: 6439848
    [No Abstract]   [Full Text] [Related]  

  • 9. Trypanosoma cruzi calreticulin: a possible role in Chagas' disease autoimmunity.
    Ribeiro CH; López NC; Ramírez GA; Valck CE; Molina MC; Aguilar L; Rodríguez M; Maldonado I; Martínez R; González C; Troncoso R; Lavandero S; Gingras AR; Schwaeble W; Ferreira A
    Mol Immunol; 2009 Mar; 46(6):1092-9. PubMed ID: 19108895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the cellular immune response in Chagas' disease patients.
    Castes M; Araujo Z; Mosca W
    Acta Cient Venez; 1986; 37(5):547-53. PubMed ID: 3129894
    [No Abstract]   [Full Text] [Related]  

  • 11. A novel and basic mechanism of immunosuppression in Chagas' disease: Trypanosoma cruzi releases in vitro and in vivo a protein which induces T cell unresponsiveness through specific interaction with cysteine and glutathione.
    Ouaissi A; Guevara-Espinoza A; Chabé F; Gomez-Corvera R; Taibi A
    Immunol Lett; 1995 Dec; 48(3):221-4. PubMed ID: 8867855
    [No Abstract]   [Full Text] [Related]  

  • 12. Lack of cross-reactivity of lytic antibodies with bloodstream forms of Trypanosoma cruzi zymodemes generated in a mouse experimental model.
    Wallace A; Sanchez G; Venegas J; Solari A
    Exp Parasitol; 1995 Mar; 80(2):176-85. PubMed ID: 7895829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-dependent cytolysis of Trypanosoma cruzi by human polymorphonuclear leukocytes.
    Olabuenaga SE; Cardoni RL; Segura EL; Riera NE; de Bracco MM
    Cell Immunol; 1979 Jun; 45(1):85-93. PubMed ID: 110466
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of Trypanosoma cruzi antigens recognized by T cells and immune sera from chagasic patients.
    Gazzinelli RT; Leme VM; Cançado JR; Gazzinelli G; Scharfstein J
    Mem Inst Oswaldo Cruz; 1988 Nov; 83 Suppl 1():272-9. PubMed ID: 3150992
    [No Abstract]   [Full Text] [Related]  

  • 15. Cell-mediated immunity in Chagas' disease: Alterations induced by treatment with a trypanocidal drug (nifurtimox).
    Lelchuk R; Cardoni RL; Fuks AS
    Clin Exp Immunol; 1977 Dec; 30(3):434-8. PubMed ID: 414867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of aberrant T-cell responses in Chagas disease.
    DosReis GA; Freire-de-Lima CG; Nunes MP; Lopes MF
    Trends Parasitol; 2005 May; 21(5):237-43. PubMed ID: 15837613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trypanosoma cruzi: immunological consequences of parasite modification of host cells.
    Ribeiro Dos Santos R; Hudson L
    Clin Exp Immunol; 1980 Apr; 40(1):36-41. PubMed ID: 6771080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Circulating antigens of Trypanosoma cruzi in patients with Chagas' disease in an endemic area].
    Alonso JM; Pividori S; Guilleron C
    Medicina (B Aires); 1986; 46(1):69-72. PubMed ID: 3100908
    [No Abstract]   [Full Text] [Related]  

  • 19. Macrophages in experimental Chagas' disease.
    Kuhn RE
    Immunol Ser; 1994; 60():495-502. PubMed ID: 8251589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies in Trypanosoma cruzi infection.
    Sánchez DO; González Cappa SM
    Medicina (B Aires); 1983; 43(1):41-6. PubMed ID: 6410148
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.